

## Details of Q3 FY25 Quarterly Report, Appendix 4C & Webinar

**Microba Life Sciences Limited** (ASX: MAP) (“Microba” or the “Company”) advises that it will release its Q3 FY25 Quarterly Activities Report, Appendix 4C and Quarterly Investor Presentation on Wednesday, 30 April 2025.

The Company will also release its Quarterly Investor Video Presentation. The details of the video presentation are below.

### Quarterly Investor Video Presentation

**Presenting:** CEO, Dr Luke Reid

**Release Time & Date:** 9:00am AEST on Wednesday, 30 April 2025

**Video Presentation Access:** The Quarterly Investor Video Presentation can be accessed via Microba’s Investor Hub at the following link at 9:00am AEST on Wednesday, 30 April 2025: <https://ir.microba.com/webinars/LPZoBy-q3-fy25-quarterly-investor-video-presentation>

### Investor Q&As

We invite investors and interested parties to submit questions prior to the Quarterly Investor Presentation through the ‘Ask a question’ section of Microba’s interactive investor platform by following this link:

<https://ir.microba.com/webinars/LPZoBy-q3-fy25-quarterly-investor-video-presentation>

### Microba’s Investor Hub

To be notified when the Q3 FY25 Quarterly Report, Appendix 4C and Investor Presentation as well as other announcements are released, please sign up to Microba’s Investor Hub by following the instructions below.

1. Visit <https://ir.microba.com/welcome>
2. Follow the prompts to sign up for an account.
3. Complete your account profile.

*This announcement has been authorised for release by the Chair and CEO.*

**For further information, please contact:**

**Dr Luke Reid**

Chief Executive Officer

[luke.reid@microba.com](mailto:luke.reid@microba.com)

<https://ir.microba.com/welcome>

### About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit [www.microba.com](http://www.microba.com)



#### JOIN MICROBA’S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit [ir.microba.com/welcome](https://ir.microba.com/welcome)

**Microba Life Sciences Ltd** | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621